An overview to pharmaceutical financing in Iran
-
Mehdi Varmaghani
,
Amir Hashemi-Meshkini
,
Akbar Abdollahiasl
,
Elham Heidari
,
Hedieh-Sadat Zekri
,
Saeed Yaghoubifard
,
Farid Dorkoosh
Abstract
Pharmaceutical expenditure is a substantial part of the health-care system budget. In Iran, people are paying about half of total pharmaceutical expenditure out of their pocket. In this study, we reviewed the Iranian pharmaceuticals financing system including the current situation and the relevant policies. We also provide an overview about the new health-care system reform and its challenges ahead.(1) Murray CJ, Evans DB. Health systems performance assessment: debates, methods and empiricism. Geneva, Switzerland: World Health Organization; 2003.
(2) Carrin G, Waelkens MP, Criel B. Community-based health insurance in developing countries: a study of its contribution to the performance of health financing systems. Trop Med Int Health 2005; 10(8): 799-811.
(3) Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21(2): 89-103.
(4) Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countries. Daru 2013; 21(1): 52.
(5) Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M. Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int Health Hum Rights 2005; 5(1): 5.
(6) Zaboli P, Hashemi-Meshkini A, Varmaghani M, Gholami H, Vazirian I, Zekri HS, et al. Pharmaceutical laws and regulations in Iran: An overview. J Res Pharm Pract 2016; 5(3): 155-61.
(7) Dindoust P. Pricing and reimbursement of pharmaceuticals in Iran and selected countries to design a new mode: A comparative [PhD Thesis]. Tehran, Iran: Iran University of Medical Sciences; 2009. [In Persian].
(8) Hashemi-Meshkini A, Keshavarz K, Nikfar S, Vazirian I, Kebriaeezadeh A. Pharmacists remuneration models in Iran and selected countries: a comparative study. Iran J Pharm Res 2013; 12(4): 995-64.
(9) Varmaghani M, Meshkini AH, Farzadfar F, Yousefi M, Yaghoubifard S, Varahrami V, et al. Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis. J Res Pharm Pract 2015; 4(2): 51-6.
(10) World Health Organization. Medicine prices, availability, affordability and price components Islamic Republic of Iran. Cairo, Egypt: WHO Regional Office for the Eastern Mediterranean; 2009.
(11) Hashemi-Meshkini A. making the public health and industrial objectives balanced; the big challenge of Iran’s food and drug organization. Iran J Public Health 2014; 43(5): 693-5.
(12) Davari M, Haycox A, Walley T. The Iranian health insurance system; past experiences, present challenges and future strategies. Iran J Public Health 2012; 41(9): 1-9.
(13) Khoshakhlagh M. National Health Accounts during 2000-2013. Amar 2016; 19: 24-6.
(14) Rashidian A, Khosravi A, Khabiri R, Khodayari Moez E, Elahi E, Arab M, et al. Republic of Iran's Multiple Indicator Demograpphic and Healh Survey (IrMIDHS) 2010. Tehran, Iran: Ministry of Health and Medical Education; 2012. [In Persian].
(15) Delgoshaei B, Tourani S, Khalesi N, Dindoust P. Pricing and reimbursement of pharmaceuticals in iran and selected countries: a comparative study. J Health Adm 2006; 8(22): 55-66. [In Persian].
(16) Ansaripour A, Uyl-de Groot CA, Steenhoek A, Redekop WK. The drug reimbursement decision-making system in Iran. Value Health Reg Issues 2014; 3: 174-81.
(17) Moradi-Lakeh M, Vosoogh-Moghaddam A. Health sector evolution plan in Iran; equity and sustainability concerns. Int J Health Policy Manag 2015; 4(10): 637-40.
| Files | ||
| Issue | Vol 2 No 1/2 (2016) | |
| Section | Review Article(s) | |
| Keywords | ||
| Pharmaceutical Financing Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
